Charles River Laboratories International (NYSE:CRL) Issues FY 2025 Earnings Guidance

Charles River Laboratories International (NYSE:CRL - Get Free Report) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided EPS guidance of 9.300-9.800 for the period, compared to the consensus EPS estimate of 9.310. The company issued revenue guidance of $3.8 billion-$3.9 billion, compared to the consensus revenue estimate of $3.8 billion.

Wall Street Analysts Forecast Growth

A number of research firms have commented on CRL. JPMorgan Chase & Co. lowered their price objective on Charles River Laboratories International from $175.00 to $165.00 and set a "neutral" rating on the stock in a research note on Thursday, February 20th. Evercore ISI raised Charles River Laboratories International from an "in-line" rating to an "outperform" rating and set a $170.00 target price on the stock in a report on Thursday. The Goldman Sachs Group downgraded Charles River Laboratories International from a "buy" rating to a "neutral" rating and reduced their target price for the company from $190.00 to $170.00 in a report on Friday, March 21st. Robert W. Baird raised their target price on Charles River Laboratories International from $118.00 to $140.00 and gave the company a "neutral" rating in a report on Thursday. Finally, Mizuho reduced their target price on Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating on the stock in a report on Wednesday, April 9th. One investment analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and one has issued a buy rating to the company. According to data from MarketBeat.com, Charles River Laboratories International presently has a consensus rating of "Hold" and an average target price of $176.00.

Charles River Laboratories International Price Performance

Shares of NYSE CRL traded up $5.36 during mid-day trading on Monday, hitting $144.15. 1,106,235 shares of the stock traded hands, compared to its average volume of 967,340. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.41 and a quick ratio of 1.14. Charles River Laboratories International has a twelve month low of $91.86 and a twelve month high of $254.15. The company has a market cap of $7.08 billion, a PE ratio of 961.03, a price-to-earnings-growth ratio of 4.54 and a beta of 1.50. The firm has a 50 day simple moving average of $138.40 and a two-hundred day simple moving average of $166.20.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its earnings results on Wednesday, May 7th. The medical research company reported $2.34 EPS for the quarter, topping the consensus estimate of $2.06 by $0.28. The firm had revenue of $984.17 million for the quarter, compared to the consensus estimate of $942.34 million. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The business's quarterly revenue was down 2.7% compared to the same quarter last year. During the same period in the previous year, the business earned $2.27 EPS. As a group, equities research analysts forecast that Charles River Laboratories International will post 9.36 EPS for the current fiscal year.

Insiders Place Their Bets

In other Charles River Laboratories International news, COO Birgit Girshick acquired 1,514 shares of the stock in a transaction dated Thursday, February 20th. The stock was purchased at an average cost of $164.63 per share, with a total value of $249,249.82. Following the transaction, the chief operating officer now owns 55,058 shares in the company, valued at approximately $9,064,198.54. The trade was a 2.83% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Joseph W. Laplume sold 4,400 shares of Charles River Laboratories International stock in a transaction dated Thursday, February 20th. The stock was sold at an average price of $162.50, for a total value of $715,000.00. Following the completion of the transaction, the executive vice president now directly owns 20,013 shares of the company's stock, valued at approximately $3,252,112.50. This trade represents a 18.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 1.30% of the company's stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).